Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Zenas BioPharma Raises $118 Million for Global Autoimmune Portfolio

publication date: Nov 10, 2022

Zenas BioPharma, a Boston-Shanghai biopharma, received $118 million in proceeds from Series B preferred shares. A two-year old company, Zenas will use the capital for a global Phase III trial of its lead candidate, obexelimab, in patients with IgG4-related disease. The company also plans to advance other autoimmune disease programs into clinical development next year. In March 2021, Zenas broke cover with a portfolio of seven in-licensed immune and rare disease candidates. The B round was led by Enavate Sciences and included participation from a long list of new and existing investors. More details....

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital